<DOC>
	<DOCNO>NCT01064154</DOCNO>
	<brief_summary>Carvedilol 25 mg Film-coated Tablets , Bioequivalence Study Of Dr. Reddys Under Fasting Conditions</brief_summary>
	<brief_title>Carvedilol 25 mg Film-coated Tablets , Bioequivalence Study Dr. Reddys Under Fasting Conditions</brief_title>
	<detailed_description>A Randomized , two-way Crossover , Bioequivalence Study Carvedilol 25 mg Film-coated Tablets COREG® 25 mg Film-coated Tablets Administered 1 x 25 mg Film-coated Tablet Healthy Subjects Under Fasting Conditions . Treatment Duration : Single dose two treatment ( A , B ) two different occasion , separate washout period 7 day .</detailed_description>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may do use different medium ( e.g . radio , newspaper , Anapharm Inc. Website , Anapharm Inc. volunteer ' data base ) . Subjects must meet follow criterion order include study : Subjects females and/or male , smoker nonsmoker , 18 year age &amp; old . Female subject postmenopausal/surgically sterilize . Postmenopausal status define absence menses past 12 month hysterectomy bilateral oophorectomy least 6 month ago . Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Subjects follow applies exclude study : Clinically significant illnesses/surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Subjects clinically significant history second thirddegree AV block , sick sinus syndrome severe bradycardia patient cardiogenic shock decompensated heart failure . Subjects history hepatic failure . Presence history liver disease , cardiovascular disease , diabetes , hyperthyroidism aDd peripheral vascular disease . Positive urine drug screen positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure &lt; ll0 140 mmHg , diastolic blood pressure &lt; 70 90 mmHg ; heart rate &lt; 60 100 bpm ) screening . Subjects BMI ≥30.0 . History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . History allergic reaction carvedilol betablocking agent ( e.g . propranolol , labetalol , acebutolol , atenolol , esmolol , metoprolol , oxprenolol , timolol , pindolol , betaxolol , levobunolol nadolol ) . History pulmonary bronchospastic disease ( include asthma ) . Subjects pheochromocytoma . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) , use investigational drug participation investigational study within 30 day prior administration study medication . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural product , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : less 300 mL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . Smoking 25 cigarette per day . Subjects consume food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . Additional exclusion criterion female : • Breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>